-
2
-
-
84875804295
-
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
-
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374-1403.
-
(2013)
Eur J Cancer
, vol.49
, pp. 1374-1403
-
-
Ferlay, J.1
Steliarova-Foucher, E.2
Lortet-Tieulent, J.3
-
3
-
-
84902147062
-
Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States
-
Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913-2921.
-
(2014)
Cancer Res
, vol.74
, pp. 2913-2921
-
-
Rahib, L.1
Smith, B.D.2
Aizenberg, R.3
-
4
-
-
84884189727
-
Long-term colorectal-cancer incidence and mortality after lower endoscopy
-
Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369: 1095-1105.
-
(2013)
N Engl J Med
, vol.369
, pp. 1095-1105
-
-
Nishihara, R.1
Wu, K.2
Lochhead, P.3
-
5
-
-
84891372505
-
Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE-5 - A population-based study
-
De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol. 2014;15:23-34.
-
(2014)
Lancet Oncol
, vol.15
, pp. 23-34
-
-
De Angelis, R.1
Sant, M.2
Coleman, M.P.3
-
6
-
-
0026721532
-
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project
-
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol. 1992;10: 896-903.
-
(1992)
J Clin Oncol
, vol.10
, pp. 896-903
-
-
-
7
-
-
34447277453
-
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial
-
Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007;370:135-142.
-
(2007)
Lancet
, vol.370
, pp. 135-142
-
-
Koopman, M.1
Antonini, N.F.2
Douma, J.3
-
8
-
-
84908573757
-
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial
-
Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065-1075.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1065-1075
-
-
Heinemann, V.1
Von Weikersthal, L.F.2
Decker, T.3
-
9
-
-
84907027361
-
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) [abstr LBA3]
-
Venook AP, Niedzwiecki D, Lenz HJ. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) [abstr LBA3]. J Clin Oncol. 2014;32(Suppl):5.
-
(2014)
J Clin Oncol
, vol.32
, pp. 5
-
-
Venook, A.P.1
Niedzwiecki, D.2
Lenz, H.J.3
-
10
-
-
0037022292
-
Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis
-
Roberts RB, Min L, Washington MK, et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci U S A. 2002;99:1521-1526.
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 1521-1526
-
-
Roberts, R.B.1
Min, L.2
Washington, M.K.3
-
11
-
-
18344390418
-
ERBB receptors and cancer: The complexity of targeted inhibitors
-
Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341-354.
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 341-354
-
-
Hynes, N.E.1
Lane, H.A.2
-
12
-
-
0028168569
-
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity
-
Guy PM, Platko JV, Cantley LC, et al. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A. 1994;91:8132-8136.
-
(1994)
Proc Natl Acad Sci U S A
, vol.91
, pp. 8132-8136
-
-
Guy, P.M.1
Platko, J.V.2
Cantley, L.C.3
-
13
-
-
2342591455
-
The discovery of receptor tyrosine kinases: Targets for cancer therapy
-
Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4: 361-370.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 361-370
-
-
Gschwind, A.1
Fischer, O.M.2
Ullrich, A.3
-
14
-
-
0020068317
-
A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles
-
Cohen S, Ushiro H, Stoscheck C, et al. A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem. 1982;257:1523-1531.
-
(1982)
J Biol Chem
, vol.257
, pp. 1523-1531
-
-
Cohen, S.1
Ushiro, H.2
Stoscheck, C.3
-
15
-
-
17444403242
-
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
-
Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7:301-311.
-
(2005)
Cancer Cell
, vol.7
, pp. 301-311
-
-
Li, S.1
Schmitz, K.R.2
Jeffrey, P.D.3
-
16
-
-
33745828702
-
EGF-ERBB signalling: Towards the systems level
-
Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7:505-516.
-
(2006)
Nat Rev Mol Cell Biol
, vol.7
, pp. 505-516
-
-
Citri, A.1
Yarden, Y.2
-
17
-
-
0032795261
-
Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development
-
Luetteke NC, Qiu TH, Fenton SE, et al. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development. 1999; 126:2739-2750.
-
(1999)
Development
, vol.126
, pp. 2739-2750
-
-
Luetteke, N.C.1
Qiu, T.H.2
Fenton, S.E.3
-
18
-
-
0027297643
-
TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice
-
Luetteke NC, Qiu TH, Peiffer RL, et al. TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell. 1993;73:263-278.
-
(1993)
Cell
, vol.73
, pp. 263-278
-
-
Luetteke, N.C.1
Qiu, T.H.2
Peiffer, R.L.3
-
19
-
-
0037453001
-
Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function
-
Iwamoto R, Yamazaki S, Asakura M, et al. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci U S A. 2003;100:3221-3226.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, pp. 3221-3226
-
-
Iwamoto, R.1
Yamazaki, S.2
Asakura, M.3
-
20
-
-
14644445166
-
Epidermal growth factor receptor signaling in colorectal cancer: Preclinical data and therapeutic perspectives
-
Spano JP, Fagard R, Soria JC, et al. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol. 2005;16:189-194.
-
(2005)
Ann Oncol
, vol.16
, pp. 189-194
-
-
Spano, J.P.1
Fagard, R.2
Soria, J.C.3
-
21
-
-
20144381957
-
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
-
Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23:1803-1810.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1803-1810
-
-
Chung, K.Y.1
Shia, J.2
Kemeny, N.E.3
-
22
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1626-1634
-
-
Amado, R.G.1
Wolf, M.2
Peeters, M.3
-
23
-
-
25144491785
-
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: An immunohistochemical and chromogenic in situ hybridization study
-
Shia J, Klimstra DS, Li AR, et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol. 2005;18:1350-1356.
-
(2005)
Mod Pathol
, vol.18
, pp. 1350-1356
-
-
Shia, J.1
Klimstra, D.S.2
Li, A.R.3
-
24
-
-
53249123419
-
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: A fluorescent in situ hybridization study
-
Personeni N, Fieuws S, Piessevaux H, et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res. 2008;14:5869-5876.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 5869-5876
-
-
Personeni, N.1
Fieuws, S.2
Piessevaux, H.3
-
25
-
-
41549097718
-
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
-
Cappuzzo F, Finocchiaro G, Rossi E, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol. 2008;19:717-723.
-
(2008)
Ann Oncol
, vol.19
, pp. 717-723
-
-
Cappuzzo, F.1
Finocchiaro, G.2
Rossi, E.3
-
26
-
-
34548258303
-
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
-
Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol. 2007;25:3238-3245.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3238-3245
-
-
Sartore-Bianchi, A.1
Moroni, M.2
Veronese, S.3
-
27
-
-
19244366949
-
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
-
Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000;18:904-914.
-
(2000)
J Clin Oncol
, vol.18
, pp. 904-914
-
-
Baselga, J.1
Pfister, D.2
Cooper, M.R.3
-
28
-
-
84953909498
-
-
Accessed October 28, 2015
-
Cetuximab FDA label, 2015. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo. Accessed October 28, 2015.
-
(2015)
Cetuximab FDA Label
-
-
-
29
-
-
0035117355
-
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
-
Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38:17-23.
-
(2001)
Crit Rev Oncol Hematol
, vol.38
, pp. 17-23
-
-
Yang, X.D.1
Jia, X.C.2
Corvalan, J.R.3
-
30
-
-
0033559606
-
Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy
-
Yang XD, Jia XC, Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 1999; 59:1236-1243.
-
(1999)
Cancer Res
, vol.59
, pp. 1236-1243
-
-
Yang, X.D.1
Jia, X.C.2
Corvalan, J.R.3
-
31
-
-
84953909499
-
-
Accessed October 28, 2015
-
Panitumumab FDA label, 2015. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125147s200lbl.pdf. Accessed October 28, 2015.
-
(2015)
Panitumumab FDA Label
-
-
-
32
-
-
10744221013
-
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
-
Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004;58:984-990.
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.58
, pp. 984-990
-
-
Foon, K.A.1
Yang, X.D.2
Weiner, L.M.3
-
33
-
-
4143050397
-
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer
-
Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 2004;22:3003-3015.
-
(2004)
J Clin Oncol
, vol.22
, pp. 3003-3015
-
-
Rowinsky, E.K.1
Schwartz, G.H.2
Gollob, J.A.3
-
34
-
-
38949178132
-
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies
-
Weiner LM, Belldegrun AS, Crawford J, et al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res. 2008;14:502-508.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 502-508
-
-
Weiner, L.M.1
Belldegrun, A.S.2
Crawford, J.3
-
35
-
-
61349191606
-
An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors
-
Stephenson JJ, Gregory C, Burris H, et al. An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors. Clin Colorectal Cancer. 2009;8:29-37.
-
(2009)
Clin Colorectal Cancer
, vol.8
, pp. 29-37
-
-
Stephenson, J.J.1
Gregory, C.2
Burris, H.3
-
36
-
-
84903694472
-
Final results from PRIME: Randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
-
Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25: 1346-1355.
-
(2014)
Ann Oncol
, vol.25
, pp. 1346-1355
-
-
Douillard, J.Y.1
Siena, S.2
Cassidy, J.3
-
37
-
-
84905870196
-
PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer
-
Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32:2240-2247.
-
(2014)
J Clin Oncol
, vol.32
, pp. 2240-2247
-
-
Schwartzberg, L.S.1
Rivera, F.2
Karthaus, M.3
-
38
-
-
38049044037
-
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
-
Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol. 2008;19(1):92-98.
-
(2008)
Ann Oncol
, vol.19
, Issue.1
, pp. 92-98
-
-
Van Cutsem, E.1
Siena, S.2
Humblet, Y.3
-
39
-
-
84857050570
-
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
-
Kohne CH, Hofheinz R, Mineur L, et al. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol. 2012;138:65-72.
-
(2012)
J Cancer Res Clin Oncol
, vol.138
, pp. 65-72
-
-
Kohne, C.H.1
Hofheinz, R.2
Mineur, L.3
-
40
-
-
35648941728
-
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study
-
Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol. 2007;25:4557-4561.
-
(2007)
J Clin Oncol
, vol.25
, pp. 4557-4561
-
-
Saltz, L.B.1
Lenz, H.J.2
Kindler, H.L.3
-
41
-
-
59949102930
-
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
-
Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672-680.
-
(2009)
J Clin Oncol
, vol.27
, pp. 672-680
-
-
Hecht, J.R.1
Mitchell, E.2
Chidiac, T.3
-
42
-
-
59749091477
-
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
-
Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360:563-572.
-
(2009)
N Engl J Med
, vol.360
, pp. 563-572
-
-
Tol, J.1
Koopman, M.2
Cats, A.3
-
43
-
-
84925968868
-
Pragmatic issues in biomarker evaluation for targeted therapies in cancer
-
de Gramont A, Watson S, Ellis LM, et al. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol. 2015;12:197-212.
-
(2015)
Nat Rev Clin Oncol
, vol.12
, pp. 197-212
-
-
De Gramont, A.1
Watson, S.2
Ellis, L.M.3
-
45
-
-
54949085398
-
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
-
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.
-
(2008)
N Engl J Med
, vol.359
, pp. 1757-1765
-
-
Karapetis, C.S.1
Khambata-Ford, S.2
Jonker, D.J.3
-
46
-
-
78049341541
-
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
-
De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304: 1812-1820.
-
(2010)
JAMA
, vol.304
, pp. 1812-1820
-
-
De Roock, W.1
Jonker, D.J.2
Di Nicolantonio, F.3
-
47
-
-
84862999938
-
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
-
Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532-536.
-
(2012)
Nature
, vol.486
, pp. 532-536
-
-
Misale, S.1
Yaeger, R.2
Hobor, S.3
-
48
-
-
84953909500
-
-
Vienna, Austria
-
Segelov E, Thavaneswaran S, Waring P, et al. Abstract 32LBA. The AGITG ICECREAM Study: the Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation - analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. Paper presented at: European Cancer Congress, 2015, Vienna, Austria.
-
(2015)
Abstract 32LBA. The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation - Analysis of Outcomes in Patients with Refractory Metastatic Colorectal Cancer Harbouring The KRAS G13D Mutation. Paper Presented At: European Cancer Congress
-
-
Segelov, E.1
Thavaneswaran, S.2
Waring, P.3
-
49
-
-
84883680951
-
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
-
Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369: 1023-1034.
-
(2013)
N Engl J Med
, vol.369
, pp. 1023-1034
-
-
Douillard, J.Y.1
Oliner, K.S.2
Siena, S.3
-
50
-
-
79959337678
-
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial
-
Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377:2103-2114.
-
(2011)
Lancet
, vol.377
, pp. 2103-2114
-
-
Maughan, T.S.1
Adams, R.A.2
Smith, C.G.3
-
51
-
-
84925105975
-
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
-
Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015;51:587-594.
-
(2015)
Eur J Cancer
, vol.51
, pp. 587-594
-
-
Pietrantonio, F.1
Petrelli, F.2
Coinu, A.3
-
52
-
-
84903301924
-
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
-
Therkildsen C, Bergmann TK, Henrichsen-Schnack T, et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol. 2014;53:852-864.
-
(2014)
Acta Oncol
, vol.53
, pp. 852-864
-
-
Therkildsen, C.1
Bergmann, T.K.2
Henrichsen-Schnack, T.3
-
53
-
-
84863230465
-
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
-
Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100-113.
-
(2012)
Nature
, vol.483
, pp. 100-113
-
-
Prahallad, A.1
Sun, C.2
Huang, S.3
-
54
-
-
84953856186
-
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
-
Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306-1315.
-
(2015)
Lancet Oncol
, vol.16
, pp. 1306-1315
-
-
Cremolini, C.1
Loupakis, F.2
Antoniotti, C.3
-
57
-
-
84953909501
-
-
Paper presented at: AACR 106th Annual Meeting, April 18-22, Philadelphia, PA [Abst #CT136]
-
Schellens JH, Van Geel R, Bendell JC, et al. Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer. Paper presented at: AACR 106th Annual Meeting, April 18-22, 2015, Philadelphia, PA [Abst #CT136].
-
(2015)
Final Biomarker Analysis of the Phase I Study of the Selective BRAF V600 Inhibitor Encorafenib (LGX818) Combined with Cetuximab with Or without the α-specific PI3K Inhibitor Alpelisib (BYL719) in Patients with Advanced Braf-Mutant Colorectal Cancer
-
-
Schellens, J.H.1
Van Geel, R.2
Bendell, J.C.3
-
58
-
-
84969302810
-
First-line treatment with modified FOLFOX6 (MFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): Tumor response outcomes beyond RECIST [abstr 660]
-
Rivera F, Karthaus M, Hecht JR. First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): tumor response outcomes beyond RECIST [abstr 660]. J Clin Oncol. 2015;33(Suppl 3).
-
(2015)
J Clin Oncol
, vol.33
-
-
Rivera, F.1
Karthaus, M.2
Hecht, J.R.3
-
59
-
-
84925324704
-
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer
-
Van Cutsem E, Lenz HJ, Kohne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33:692-700.
-
(2015)
J Clin Oncol
, vol.33
, pp. 692-700
-
-
Van Cutsem, E.1
Lenz, H.J.2
Kohne, C.H.3
-
60
-
-
84954202031
-
Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015
-
Allegra CJ, Rumble RB, Hamilton SR, et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. Epub October 5, 2015.
-
(2015)
J Clin Oncol. Epub October
, pp. 5
-
-
Allegra, C.J.1
Rumble, R.B.2
Hamilton, S.R.3
-
61
-
-
84861704697
-
KRASness and PIK3CAness in patients with advanced colorectal cancer: Outcome after treatment with early-phase trials with targeted pathway inhibitors
-
Garrido-Laguna I, Hong DS, Janku F, et al. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One. 2012;7:e38033.
-
(2012)
Plos One
, vol.7
-
-
Garrido-Laguna, I.1
Hong, D.S.2
Janku, F.3
-
62
-
-
20444374445
-
Mutant PIK3CA promotes cell growth and invasion of human cancer cells
-
Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7:561-573.
-
(2005)
Cancer Cell
, vol.7
, pp. 561-573
-
-
Samuels, Y.1
Diaz, L.A.2
Schmidt-Kittler, O.3
-
63
-
-
84863922124
-
Comprehensive molecular characterization of human colon and rectal cancer
-
Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330-337.
-
(2012)
Nature
, vol.487
, pp. 330-337
-
-
-
64
-
-
77955277111
-
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
-
De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753-762.
-
(2010)
Lancet Oncol
, vol.11
, pp. 753-762
-
-
De Roock, W.1
Claes, B.2
Bernasconi, D.3
-
65
-
-
84893461612
-
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer - Results from NCIC CTG/AGITG CO.17
-
Karapetis CS, Jonker D, Daneshmand M, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer - results from NCIC CTG/AGITG CO.17. Clin Cancer Res. 2014;20:744-753.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 744-753
-
-
Karapetis, C.S.1
Jonker, D.2
Daneshmand, M.3
-
67
-
-
84878862323
-
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
-
Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013;3:658-673.
-
(2013)
Cancer Discov
, vol.3
, pp. 658-673
-
-
Bardelli, A.1
Corso, S.2
Bertotti, A.3
-
68
-
-
84899981129
-
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study
-
Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014;15:569-579.
-
(2014)
Lancet Oncol
, vol.15
, pp. 569-579
-
-
Price, T.J.1
Peeters, M.2
Kim, T.W.3
-
69
-
-
84856239290
-
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab
-
Wadlow RC, Hezel AF, Abrams TA, et al. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist. 2012;17:14.
-
(2012)
Oncologist
, vol.17
, pp. 14
-
-
Wadlow, R.C.1
Hezel, A.F.2
Abrams, T.A.3
-
70
-
-
84856717005
-
Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer
-
Montagut C, Dalmases A, Bellosillo B, et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012;18:221-223.
-
(2012)
Nat Med
, vol.18
, pp. 221-223
-
-
Montagut, C.1
Dalmases, A.2
Bellosillo, B.3
-
71
-
-
84932606172
-
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer
-
Arena S, Bellosillo B, Siravegna G, et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res. 2015;21(9):2157-2166.
-
(2015)
Clin Cancer Res
, vol.21
, Issue.9
, pp. 2157-2166
-
-
Arena, S.1
Bellosillo, B.2
Siravegna, G.3
-
72
-
-
84969304791
-
Prevalence and outcomes of patients (Pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). J Clin Oncol. 2015;33(Suppl): Abstr e14623
-
Price TJ, Newhall K, Peeters M, et al. Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). J Clin Oncol. 2015;33(Suppl): abstr e14623. ASCO Annual Meeting Proceedings.
-
ASCO Annual Meeting Proceedings
-
-
Price, T.J.1
Newhall, K.2
Peeters, M.3
-
73
-
-
0027109075
-
Cancer. P53, guardian of the genome
-
Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358: 15-16.
-
(1992)
Nature
, vol.358
, pp. 15-16
-
-
Lane, D.P.1
-
74
-
-
65349149003
-
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
-
Oden-Gangloff A, Di Fiore F, Bibeau F, et al. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer. 2009;100:1330-1335.
-
(2009)
Br J Cancer
, vol.100
, pp. 1330-1335
-
-
Oden-Gangloff, A.1
Di Fiore, F.2
Bibeau, F.3
-
75
-
-
84877087305
-
Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer
-
Peeters M, Oliner KS, Parker A, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res. 2013;19:1902-1912.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 1902-1912
-
-
Peeters, M.1
Oliner, K.S.2
Parker, A.3
-
76
-
-
84939181687
-
HER2 activating mutations are targets for colorectal cancer treatment
-
Kavuri SM, Jain N, Galimi F, et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 2015;5:832-841.
-
(2015)
Cancer Discov
, vol.5
, pp. 832-841
-
-
Kavuri, S.M.1
Jain, N.2
Galimi, F.3
-
77
-
-
84944079826
-
The genomic landscape of response to EGFR blockade in colorectal cancer
-
Bertotti A, Papp E, Jones S, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526:263-267.
-
(2015)
Nature
, vol.526
, pp. 263-267
-
-
Bertotti, A.1
Papp, E.2
Jones, S.3
-
78
-
-
77950495095
-
Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer
-
Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351-1357.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1351-1357
-
-
Lacouture, M.E.1
Mitchell, E.P.2
Piperdi, B.3
-
79
-
-
84969302214
-
Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (MCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study [abstr LBA444]
-
Tejpar S, Lenz HJ, Kohne CH. Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: new results from the OPUS study [abstr LBA444]. J Clin Oncol. 2014;32(Suppl 3).
-
(2014)
J Clin Oncol
, vol.32
-
-
Tejpar, S.1
Lenz, H.J.2
Kohne, C.H.3
-
80
-
-
84923013251
-
Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases
-
Mao C, Wu XY, Yang ZY, et al. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep. 2015;5:8065.
-
(2015)
Sci Rep
, vol.5
, pp. 8065
-
-
Mao, C.1
Wu, X.Y.2
Yang, Z.Y.3
-
81
-
-
84925701525
-
Stromal contribution to the colorectal cancer transcriptome
-
Isella C, Terrasi A, Bellomo SE, et al. Stromal contribution to the colorectal cancer transcriptome. Nat Genet. 2015;47:312-319.
-
(2015)
Nat Genet
, vol.47
, pp. 312-319
-
-
Isella, C.1
Terrasi, A.2
Bellomo, S.E.3
|